Bioactivation of the Anticancer Agent CPT-11 to SN-38 by Human Hepatic Microsomal Carboxylesterases and the in VitroAssessment of Potential Drug Interactions

Abstract

Human hepatic microsomes were used to investigate the carboxylesterase-mediated bioactivation of CPT-11 to the active metabolite, SN-38. SN-38 formation velocity was determined by HPLC over a concentration range of 0.25–200 μM CPT-11. Biphasic Eadie Hofstee plots were observed in seven donors, suggesting that two isoforms catalyzed the reaction. Analysis by nonlinear least squares regression gave KMestimates of 129–164 μM with a Vmax of 5.3–17 pmol/mg/min for the low affinity isoform. The high affinity isoform hadKM estimates of 1.4–3.9 μM withVmax of 1.2–2.6 pmol/mg/min. The lowKM carboxylesterase may be the main contributor to SN-38 formation at clinically relevant hepatic concentrations of CPT-11.

Using standard incubation conditions, the effects of potential inhibitors of carboxylesterase-mediated CPT-11 hydrolysis were evaluated at concentrations ≥ 21 μM. Positive controls bis-nitrophenylphosphate (BNPP) and physostigmine decreased CPT-11 hydrolysis to 1.3–3.3% and 23% of control values, respectively. Caffeine, acetylsalicylic acid, coumarin, cisplatin, ethanol, dexamethasone, 5-fluorouracil, loperamide, and prochlorperazine had no statistically significant effect on CPT-11 hydrolysis. Small decreases were observed with metoclopramide (91% of control), acetaminophen (93% of control), probenecid (87% of control), and fluoride (91% of control). Of the compounds tested above, based on these in vitro data, only the potent inhibitors of carboxylesterase (BNPP, physostigmine) have the potential to inhibit CPT-11 bioactivation if administered concurrently.

The carboxylesterase-mediated hydrolysis of α-naphthyl acetate (α-NA) was used to determine whether CPT-11 was an inhibitor of hydrolysis of high turnover substrates of carboxylesterases. Inhibition of α-NA hydrolysis by CPT-11 was determined relative to positive controls BNPP and NaF. Incubation with microsomes pretreated with CPT-11 (80–440 μM) decreased α-naphthol formation to approximately 80% of control at α-NA concentrations of 50–800 μM. The inhibitors BNPP (360 μM) and NaF (500 μM) inhibited α-naphthol formation to 9–10% of control and to 14–20% of control, respectively. Therefore, CPT-11-sensitive carboxylesterase isoforms may account for only 20% of total α-NA hydrolases. Thus, CPT-11 is unlikely to significantly inhibit high turnover, nonselective substrates of carboxylesterases.

Footnotes

  • Send reprint requests to: Dr. J. Greg Slatter, Drug Metabolism Research, Pharmacia and Upjohn Co., 301 Henrietta St., Kalamazoo MI 49007. E-mail: john.g.slatter{at}am.pnu.com.

  • 1 Present address: Department of Biopharmaceutical Sciences, University of California at San Francisco.

  • A preliminary account of this work was given at the 4th International ISSX Meeting, Abstracts #88, 218 and 219. Seattle WA, Aug 27–31, 1995.

  • Abbreviations used are::
    CPT
    camptothecin
    CPT-11
    irinotecan hydrochloride trihydrate
    EtOH
    ethanol
    ASA
    acetylsalicylic acid
    HMB
    hydroxymercuribenzote
    CMB
    chloromercuribenzoate
    HPLC
    high performance liquid chromatography
    KM
    Michaelis constant
    5-FU
    5-fluorouracil
    MeOH
    methanol
    BNPP
    bis-nitrophenylphosphate
    α-NA
    alpha naphthyl acetate
    SN-38
    active antineoplastic metabolite of CPT-11
    DMSO
    dimethylsulfoxide
    UPACS
    Upjohn Physical and Analytical Chemistry System
    V
    reaction velocity
    QC
    quality control standard
    [S]
    substrate concentration
    • Received March 28, 1997.
    • Accepted June 5, 1997.
« Previous | Next Article »Table of Contents